icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
 
 
 
ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR ± RIBAVIRIN IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION AND COMPENSATED CIRRHOSIS: THE C-ISLE STUDY
 
 
  Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
 
Mark Sulkowski,1 Curtis Cooper,2 Jean-Michel Molina,3 Susanna Naggie,4 K.C. Huang,5 Anu Osinusi,5 Luisa M. Stamm,5 Benedetta Massetto,5 John McNally,5 Diana M. Brainard,5 John G. McHutchison,5 David Wyles,6 Jurgen K. Rockstroh,7 Douglas Dieterich8
1Johns Hopkins Hospital, Baltimore, MD; 2University of Ottawa, Ontario, Canada; 3Hopital Saint-Louis, Universitť Paris-Sorbonne, Paris, France; 4Duke University Medical Center, Durham, NC;
5Gilead Sciences, Inc., Foster City, CA; 6UC San Diego School of Medicine, La Jolla, CA; 7Universitšt Bonn, Germany; 8Icahn School of Medicine at Mount Sinai, New York, NY Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
 
Graham R. Foster*, Kosh Agarwal, Matthew Cramp, Sulleman Moreea, Stephen Barclay, Jane Collier, Ashley S. Brown, Stephen D. Ryder, Andrew Ustianowski, Daniel M. Forton, Ray Fox, Fiona Gordon, William M. Rosenberg, David J. Mutimer, Jiejun Du, Christopher L. Gilbert, Ernest Asante-Appiah, Janice Wahl, Eliav Barr, Barbara Haber *Queen Mary University, London, United Kingdom

HCV1

HCV2

HCV3

HCV4

HCV5

HCV6